secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010537
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q1 net loss $2.3M, cash $6.9M; CDI-988 shows broad norovirus activity, human challenge planned
--------------------------------------------------------------------------------

- Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
- R&D expenses decreased to $1.4M from $3.0M; G&A down to $1.0M from $1.2M.
- Unrestricted cash $6.9M at March 31, 2025 vs $9.9M at Dec 31, 2024; working capital $6.9M.
- CDI-988 showed superior broad-spectrum antiviral activity against norovirus GII.17 strains; expects to report topline Phase 1 high-dose results in Q2 2025.
- Plan to initiate a U.S. human challenge study for CDI-988 as norovirus treatment and prophylaxis in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/0001641172-25-010537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer